The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Neurodegenerative Diseases Drug Market Research Report 2024
Synopsis
Neurodegenerative disease is caused by the loss of neurons and/or their myelin sheath, which worsens over time and becomes dysfunctional.
The global Neurodegenerative Diseases Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Diseases Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Diseases Drug.
Report Scope
The Neurodegenerative Diseases Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neurodegenerative Diseases Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurodegenerative Diseases Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen
Pfizer
Roche
Novartis
Sanofi
Teva Pharmaceuticals
Orion Pharma Ltd
UCB S.A
ACADIA Pharmaceuticals Inc.
Lundbeck Pharmaceuticals Italy S.p.A.
Mitsubishi Tanabe Pharma America
Segment by Type
By Drug Class
Immunomodulator
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
By Route of Administration
Oral
Injection
Transdermal
Segment by Application
Multiple Sclerosis
Parkinson’s Disease
Alzheimer’s Disease
Spinal Muscular Atrophy (SMA)
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurodegenerative Diseases Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Neurodegenerative disease is caused by the loss of neurons and/or their myelin sheath, which worsens over time and becomes dysfunctional.
The global Neurodegenerative Diseases Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Diseases Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Diseases Drug.
Report Scope
The Neurodegenerative Diseases Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neurodegenerative Diseases Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurodegenerative Diseases Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen
Pfizer
Roche
Novartis
Sanofi
Teva Pharmaceuticals
Orion Pharma Ltd
UCB S.A
ACADIA Pharmaceuticals Inc.
Lundbeck Pharmaceuticals Italy S.p.A.
Mitsubishi Tanabe Pharma America
Segment by Type
By Drug Class
Immunomodulator
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
By Route of Administration
Oral
Injection
Transdermal
Segment by Application
Multiple Sclerosis
Parkinson’s Disease
Alzheimer’s Disease
Spinal Muscular Atrophy (SMA)
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurodegenerative Diseases Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis By Drug Class
1.2.1 Global Neurodegenerative Diseases Drug Market Size Growth Rate By Drug Class: 2019 VS 2023 VS 2030
1.2.2 Immunomodulator
1.2.3 Interferons
1.2.4 Decarboxylase Inhibitors
1.2.5 Dopamine Agonists
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Diseases Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Multiple Sclerosis
1.3.3 Parkinson’s Disease
1.3.4 Alzheimer’s Disease
1.3.5 Spinal Muscular Atrophy (SMA)
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Diseases Drug Market Perspective (2019-2030)
2.2 Neurodegenerative Diseases Drug Growth Trends by Region
2.2.1 Global Neurodegenerative Diseases Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Neurodegenerative Diseases Drug Historic Market Size by Region (2019-2024)
2.2.3 Neurodegenerative Diseases Drug Forecasted Market Size by Region (2025-2030)
2.3 Neurodegenerative Diseases Drug Market Dynamics
2.3.1 Neurodegenerative Diseases Drug Industry Trends
2.3.2 Neurodegenerative Diseases Drug Market Drivers
2.3.3 Neurodegenerative Diseases Drug Market Challenges
2.3.4 Neurodegenerative Diseases Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Diseases Drug Players by Revenue
3.1.1 Global Top Neurodegenerative Diseases Drug Players by Revenue (2019-2024)
3.1.2 Global Neurodegenerative Diseases Drug Revenue Market Share by Players (2019-2024)
3.2 Global Neurodegenerative Diseases Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neurodegenerative Diseases Drug Revenue
3.4 Global Neurodegenerative Diseases Drug Market Concentration Ratio
3.4.1 Global Neurodegenerative Diseases Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Diseases Drug Revenue in 2023
3.5 Neurodegenerative Diseases Drug Key Players Head office and Area Served
3.6 Key Players Neurodegenerative Diseases Drug Product Solution and Service
3.7 Date of Enter into Neurodegenerative Diseases Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Diseases Drug Breakdown Data by Type
4.1 Global Neurodegenerative Diseases Drug Historic Market Size by Type (2019-2024)
4.2 Global Neurodegenerative Diseases Drug Forecasted Market Size by Type (2025-2030)
5 Neurodegenerative Diseases Drug Breakdown Data by Application
5.1 Global Neurodegenerative Diseases Drug Historic Market Size by Application (2019-2024)
5.2 Global Neurodegenerative Diseases Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Neurodegenerative Diseases Drug Market Size (2019-2030)
6.2 North America Neurodegenerative Diseases Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Neurodegenerative Diseases Drug Market Size by Country (2019-2024)
6.4 North America Neurodegenerative Diseases Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neurodegenerative Diseases Drug Market Size (2019-2030)
7.2 Europe Neurodegenerative Diseases Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Neurodegenerative Diseases Drug Market Size by Country (2019-2024)
7.4 Europe Neurodegenerative Diseases Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Diseases Drug Market Size (2019-2030)
8.2 Asia-Pacific Neurodegenerative Diseases Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neurodegenerative Diseases Drug Market Size (2019-2030)
9.2 Latin America Neurodegenerative Diseases Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Neurodegenerative Diseases Drug Market Size by Country (2019-2024)
9.4 Latin America Neurodegenerative Diseases Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Diseases Drug Market Size (2019-2030)
10.2 Middle East & Africa Neurodegenerative Diseases Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Detail
11.1.2 Biogen Business Overview
11.1.3 Biogen Neurodegenerative Diseases Drug Introduction
11.1.4 Biogen Revenue in Neurodegenerative Diseases Drug Business (2019-2024)
11.1.5 Biogen Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Neurodegenerative Diseases Drug Introduction
11.2.4 Pfizer Revenue in Neurodegenerative Diseases Drug Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 Roche
11.3.1 Roche Company Detail
11.3.2 Roche Business Overview
11.3.3 Roche Neurodegenerative Diseases Drug Introduction
11.3.4 Roche Revenue in Neurodegenerative Diseases Drug Business (2019-2024)
11.3.5 Roche Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Neurodegenerative Diseases Drug Introduction
11.4.4 Novartis Revenue in Neurodegenerative Diseases Drug Business (2019-2024)
11.4.5 Novartis Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Detail
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Neurodegenerative Diseases Drug Introduction
11.5.4 Sanofi Revenue in Neurodegenerative Diseases Drug Business (2019-2024)
11.5.5 Sanofi Recent Development
11.6 Teva Pharmaceuticals
11.6.1 Teva Pharmaceuticals Company Detail
11.6.2 Teva Pharmaceuticals Business Overview
11.6.3 Teva Pharmaceuticals Neurodegenerative Diseases Drug Introduction
11.6.4 Teva Pharmaceuticals Revenue in Neurodegenerative Diseases Drug Business (2019-2024)
11.6.5 Teva Pharmaceuticals Recent Development
11.7 Orion Pharma Ltd
11.7.1 Orion Pharma Ltd Company Detail
11.7.2 Orion Pharma Ltd Business Overview
11.7.3 Orion Pharma Ltd Neurodegenerative Diseases Drug Introduction
11.7.4 Orion Pharma Ltd Revenue in Neurodegenerative Diseases Drug Business (2019-2024)
11.7.5 Orion Pharma Ltd Recent Development
11.8 UCB S.A
11.8.1 UCB S.A Company Detail
11.8.2 UCB S.A Business Overview
11.8.3 UCB S.A Neurodegenerative Diseases Drug Introduction
11.8.4 UCB S.A Revenue in Neurodegenerative Diseases Drug Business (2019-2024)
11.8.5 UCB S.A Recent Development
11.9 ACADIA Pharmaceuticals Inc.
11.9.1 ACADIA Pharmaceuticals Inc. Company Detail
11.9.2 ACADIA Pharmaceuticals Inc. Business Overview
11.9.3 ACADIA Pharmaceuticals Inc. Neurodegenerative Diseases Drug Introduction
11.9.4 ACADIA Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Drug Business (2019-2024)
11.9.5 ACADIA Pharmaceuticals Inc. Recent Development
11.10 Lundbeck Pharmaceuticals Italy S.p.A.
11.10.1 Lundbeck Pharmaceuticals Italy S.p.A. Company Detail
11.10.2 Lundbeck Pharmaceuticals Italy S.p.A. Business Overview
11.10.3 Lundbeck Pharmaceuticals Italy S.p.A. Neurodegenerative Diseases Drug Introduction
11.10.4 Lundbeck Pharmaceuticals Italy S.p.A. Revenue in Neurodegenerative Diseases Drug Business (2019-2024)
11.10.5 Lundbeck Pharmaceuticals Italy S.p.A. Recent Development
11.11 Mitsubishi Tanabe Pharma America
11.11.1 Mitsubishi Tanabe Pharma America Company Detail
11.11.2 Mitsubishi Tanabe Pharma America Business Overview
11.11.3 Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Introduction
11.11.4 Mitsubishi Tanabe Pharma America Revenue in Neurodegenerative Diseases Drug Business (2019-2024)
11.11.5 Mitsubishi Tanabe Pharma America Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Neurodegenerative Diseases Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Immunomodulator
Table 3. Key Players of Interferons
Table 4. Key Players of Decarboxylase Inhibitors
Table 5. Key Players of Dopamine Agonists
Table 6. Key Players of Others
Table 7. Global Neurodegenerative Diseases Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Neurodegenerative Diseases Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Neurodegenerative Diseases Drug Market Size by Region (2019-2024) & (US$ Million)
Table 10. Global Neurodegenerative Diseases Drug Market Share by Region (2019-2024)
Table 11. Global Neurodegenerative Diseases Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 12. Global Neurodegenerative Diseases Drug Market Share by Region (2025-2030)
Table 13. Neurodegenerative Diseases Drug Market Trends
Table 14. Neurodegenerative Diseases Drug Market Drivers
Table 15. Neurodegenerative Diseases Drug Market Challenges
Table 16. Neurodegenerative Diseases Drug Market Restraints
Table 17. Global Neurodegenerative Diseases Drug Revenue by Players (2019-2024) & (US$ Million)
Table 18. Global Neurodegenerative Diseases Drug Market Share by Players (2019-2024)
Table 19. Global Top Neurodegenerative Diseases Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Drug as of 2023)
Table 20. Ranking of Global Top Neurodegenerative Diseases Drug Companies by Revenue (US$ Million) in 2023
Table 21. Global 5 Largest Players Market Share by Neurodegenerative Diseases Drug Revenue (CR5 and HHI) & (2019-2024)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Neurodegenerative Diseases Drug Product Solution and Service
Table 24. Date of Enter into Neurodegenerative Diseases Drug Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Neurodegenerative Diseases Drug Market Size by Type (2019-2024) & (US$ Million)
Table 27. Global Neurodegenerative Diseases Drug Revenue Market Share by Type (2019-2024)
Table 28. Global Neurodegenerative Diseases Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 29. Global Neurodegenerative Diseases Drug Revenue Market Share by Type (2025-2030)
Table 30. Global Neurodegenerative Diseases Drug Market Size by Application (2019-2024) & (US$ Million)
Table 31. Global Neurodegenerative Diseases Drug Revenue Market Share by Application (2019-2024)
Table 32. Global Neurodegenerative Diseases Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 33. Global Neurodegenerative Diseases Drug Revenue Market Share by Application (2025-2030)
Table 34. North America Neurodegenerative Diseases Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. North America Neurodegenerative Diseases Drug Market Size by Country (2019-2024) & (US$ Million)
Table 36. North America Neurodegenerative Diseases Drug Market Size by Country (2025-2030) & (US$ Million)
Table 37. Europe Neurodegenerative Diseases Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. Europe Neurodegenerative Diseases Drug Market Size by Country (2019-2024) & (US$ Million)
Table 39. Europe Neurodegenerative Diseases Drug Market Size by Country (2025-2030) & (US$ Million)
Table 40. Asia-Pacific Neurodegenerative Diseases Drug Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 41. Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2019-2024) & (US$ Million)
Table 42. Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2025-2030) & (US$ Million)
Table 43. Latin America Neurodegenerative Diseases Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Latin America Neurodegenerative Diseases Drug Market Size by Country (2019-2024) & (US$ Million)
Table 45. Latin America Neurodegenerative Diseases Drug Market Size by Country (2025-2030) & (US$ Million)
Table 46. Middle East & Africa Neurodegenerative Diseases Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 47. Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2019-2024) & (US$ Million)
Table 48. Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2025-2030) & (US$ Million)
Table 49. Biogen Company Detail
Table 50. Biogen Business Overview
Table 51. Biogen Neurodegenerative Diseases Drug Product
Table 52. Biogen Revenue in Neurodegenerative Diseases Drug Business (2019-2024) & (US$ Million)
Table 53. Biogen Recent Development
Table 54. Pfizer Company Detail
Table 55. Pfizer Business Overview
Table 56. Pfizer Neurodegenerative Diseases Drug Product
Table 57. Pfizer Revenue in Neurodegenerative Diseases Drug Business (2019-2024) & (US$ Million)
Table 58. Pfizer Recent Development
Table 59. Roche Company Detail
Table 60. Roche Business Overview
Table 61. Roche Neurodegenerative Diseases Drug Product
Table 62. Roche Revenue in Neurodegenerative Diseases Drug Business (2019-2024) & (US$ Million)
Table 63. Roche Recent Development
Table 64. Novartis Company Detail
Table 65. Novartis Business Overview
Table 66. Novartis Neurodegenerative Diseases Drug Product
Table 67. Novartis Revenue in Neurodegenerative Diseases Drug Business (2019-2024) & (US$ Million)
Table 68. Novartis Recent Development
Table 69. Sanofi Company Detail
Table 70. Sanofi Business Overview
Table 71. Sanofi Neurodegenerative Diseases Drug Product
Table 72. Sanofi Revenue in Neurodegenerative Diseases Drug Business (2019-2024) & (US$ Million)
Table 73. Sanofi Recent Development
Table 74. Teva Pharmaceuticals Company Detail
Table 75. Teva Pharmaceuticals Business Overview
Table 76. Teva Pharmaceuticals Neurodegenerative Diseases Drug Product
Table 77. Teva Pharmaceuticals Revenue in Neurodegenerative Diseases Drug Business (2019-2024) & (US$ Million)
Table 78. Teva Pharmaceuticals Recent Development
Table 79. Orion Pharma Ltd Company Detail
Table 80. Orion Pharma Ltd Business Overview
Table 81. Orion Pharma Ltd Neurodegenerative Diseases Drug Product
Table 82. Orion Pharma Ltd Revenue in Neurodegenerative Diseases Drug Business (2019-2024) & (US$ Million)
Table 83. Orion Pharma Ltd Recent Development
Table 84. UCB S.A Company Detail
Table 85. UCB S.A Business Overview
Table 86. UCB S.A Neurodegenerative Diseases Drug Product
Table 87. UCB S.A Revenue in Neurodegenerative Diseases Drug Business (2019-2024) & (US$ Million)
Table 88. UCB S.A Recent Development
Table 89. ACADIA Pharmaceuticals Inc. Company Detail
Table 90. ACADIA Pharmaceuticals Inc. Business Overview
Table 91. ACADIA Pharmaceuticals Inc. Neurodegenerative Diseases Drug Product
Table 92. ACADIA Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Drug Business (2019-2024) & (US$ Million)
Table 93. ACADIA Pharmaceuticals Inc. Recent Development
Table 94. Lundbeck Pharmaceuticals Italy S.p.A. Company Detail
Table 95. Lundbeck Pharmaceuticals Italy S.p.A. Business Overview
Table 96. Lundbeck Pharmaceuticals Italy S.p.A. Neurodegenerative Diseases Drug Product
Table 97. Lundbeck Pharmaceuticals Italy S.p.A. Revenue in Neurodegenerative Diseases Drug Business (2019-2024) & (US$ Million)
Table 98. Lundbeck Pharmaceuticals Italy S.p.A. Recent Development
Table 99. Mitsubishi Tanabe Pharma America Company Detail
Table 100. Mitsubishi Tanabe Pharma America Business Overview
Table 101. Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Product
Table 102. Mitsubishi Tanabe Pharma America Revenue in Neurodegenerative Diseases Drug Business (2019-2024) & (US$ Million)
Table 103. Mitsubishi Tanabe Pharma America Recent Development
Table 104. Research Programs/Design for This Report
Table 105. Key Data Information from Secondary Sources
Table 106. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurodegenerative Diseases Drug Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Neurodegenerative Diseases Drug Market Share by Type: 2023 VS 2030
Figure 3. Immunomodulator Features
Figure 4. Interferons Features
Figure 5. Decarboxylase Inhibitors Features
Figure 6. Dopamine Agonists Features
Figure 7. Others Features
Figure 8. Global Neurodegenerative Diseases Drug Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Neurodegenerative Diseases Drug Market Share by Application: 2023 VS 2030
Figure 10. Multiple Sclerosis Case Studies
Figure 11. Parkinson’s Disease Case Studies
Figure 12. Alzheimer’s Disease Case Studies
Figure 13. Spinal Muscular Atrophy (SMA) Case Studies
Figure 14. Others Case Studies
Figure 15. Neurodegenerative Diseases Drug Report Years Considered
Figure 16. Global Neurodegenerative Diseases Drug Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 17. Global Neurodegenerative Diseases Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 18. Global Neurodegenerative Diseases Drug Market Share by Region: 2023 VS 2030
Figure 19. Global Neurodegenerative Diseases Drug Market Share by Players in 2023
Figure 20. Global Top Neurodegenerative Diseases Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Drug as of 2023)
Figure 21. The Top 10 and 5 Players Market Share by Neurodegenerative Diseases Drug Revenue in 2023
Figure 22. North America Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. North America Neurodegenerative Diseases Drug Market Share by Country (2019-2030)
Figure 24. United States Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Canada Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Neurodegenerative Diseases Drug Market Share by Country (2019-2030)
Figure 28. Germany Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. France Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. U.K. Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Italy Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Russia Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Nordic Countries Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Neurodegenerative Diseases Drug Market Share by Region (2019-2030)
Figure 36. China Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Japan Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. South Korea Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. India Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Australia Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Neurodegenerative Diseases Drug Market Share by Country (2019-2030)
Figure 44. Mexico Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Brazil Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Neurodegenerative Diseases Drug Market Share by Country (2019-2030)
Figure 48. Turkey Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Neurodegenerative Diseases Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Biogen Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2019-2024)
Figure 51. Pfizer Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2019-2024)
Figure 52. Roche Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2019-2024)
Figure 53. Novartis Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2019-2024)
Figure 54. Sanofi Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2019-2024)
Figure 55. Teva Pharmaceuticals Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2019-2024)
Figure 56. Orion Pharma Ltd Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2019-2024)
Figure 57. UCB S.A Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2019-2024)
Figure 58. ACADIA Pharmaceuticals Inc. Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2019-2024)
Figure 59. Lundbeck Pharmaceuticals Italy S.p.A. Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2019-2024)
Figure 60. Mitsubishi Tanabe Pharma America Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2019-2024)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
